Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/47401
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVillaschi, Alessandro-
dc.contributor.authorBasile, Christian-
dc.contributor.authorBenson, Lina-
dc.contributor.authorGatti, Paolo-
dc.contributor.authorAbraham, William T.-
dc.contributor.authorBohm, Michael-
dc.contributor.authorBozkurt, Biykem-
dc.contributor.authorButler, Javed-
dc.contributor.authorCondorelli, Gianluigi-
dc.contributor.authorLinde, Cecilia-
dc.contributor.authorMetra, Marco-
dc.contributor.authorMULLENS, Wilfried-
dc.contributor.authorMol, Peter-
dc.contributor.authorZieroth, Shelley-
dc.contributor.authorScorza, Raffaele-
dc.contributor.authorLund, Lars H.-
dc.contributor.authorGadler, Fredrik-
dc.contributor.authorSavarese, Gianluigi-
dc.date.accessioned2025-09-26T08:11:32Z-
dc.date.available2025-09-26T08:11:32Z-
dc.date.issued2025-
dc.date.submitted2025-09-25T14:14:15Z-
dc.identifier.citationJacc-heart Failure, 13 (10) (Art N° 102515)-
dc.identifier.urihttp://hdl.handle.net/1942/47401-
dc.description.abstractBackground Guidelines' recommendations for cardiac resynchronization therapy (CRT) implantation in selected patients with heart failure (HF) exist. However, data on the best timing for CRT implantation after the achievement of stable medical therapy (SMT) and its association with outcomes are currently lacking. Objectives The aim of this study was to investigate the timing of CRT implantation after the achievement of SMT, associated patient profiles, and clinical outcomes in a real-world HF population. Methods Patients with HF treated with SMT derived from the Swedish ICD and Pacemaker Registry who received CRT between 2007 and 2020 were included in the study. Patient characteristics associated with a shorter or longer time to CRT implantation were assessed using multivariable logistic regression, and associations between the time from SMT to CRT implantation and clinical outcomes (mortality and morbidity) were analyzed using multivariable Cox regression. Results Of the 9,409 patients, 43.8% received CRT at <3 months of achieving SMT, 34.9% between 3 and 9 months, and 21.3% after 9 months. The time from SMT to CRT implantation decreased significantly over the study period. Independent determinants of shorter time to implantation included recent HF hospitalization, previous implantation of a defibrillator, and greater use of guideline-directed medical therapy, whereas a history of HF >6 months and ischemic heart disease were associated with a longer time. After adjustments, there was a 9% lower risk of cardiovascular death with a shorter time from SMT to CRT implantation of <3 months vs 3-9 months (P = 0.045). A delayed time of >9 months vs 3-9 months was associated with a 13% higher risk of cardiovascular death/HF hospitalization, a 12% higher risk of cardiovascular death (P = 0.040), and an 11% higher risk of first HF hospitalization (P = 0.013). Conclusions Time from the achievement of SMT to CRT implantation decreased over the study period. Delayed CRT implantation beyond 3 months was associated with higher cardiovascular mortality compared with earlier implantation after GDMT optimization.-
dc.description.sponsorshipFUNDING SUPPORT AND AUTHOR DISCLOSURES This study received support through grants from Medtronic, the Horizon Europe programme (project number 101095479 – MoreEUROPA), and the Swedish Heart and Lung Foundation (project number 20220680) awarded to the institution of Dr Savarese. Dr Böhm has received research support from Deutsche Forschungsgemeinschaft (SFB-TTR 219, S-01); and speaking honoraria from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Medtronic, Novartis, Servier, and Vifor Pharma; and has participated in advisory boards of Amgen, Bayer, Boehringer Ingelheim, Cytokinetics, Medtronic, Novartis, Pfizer, Recor Medical, Servier, and Vifor Pharma. Dr Bozkurt has served in consultation or advisory committee roles for Abiomed, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Daiichi Sankyo, Johnson and Johnson, Hanger Institute, Merck, Occlutech, Regeneron, Roche, Sanofi, scPharmaceuticals, Vifor Pharma, and Zoll Medical/Respicardia; and has served on the clinical event committee of Abbott Vascular and the data safety monitoring committees of Cardurion, LivaNova, Novo Nordisk, and Renovacor. Dr Butler has served as a consultant for Abbott, American Regent, Amgen, Applied Therapeutics, AskBio, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, CardioCell, Cardior, CSL Behring, CVRx, Cytokinetics, Daxor, Edwards Lifesciences, Element Science, Faraday Pharmaceuticals, Foundry, G3P Pharmaceuticals, Innolife, Impulse Dynamics, Imbria Pharmaceuticals, Inventiva, Ionis Pharmaceuticals, Lexicon Pharmaceuticals, Eli Lilly, LivaNova, Janssen, Medtronic, Merck, Occlutech, Owkin, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Regeneron, Renibus Therapeutics, Roche, Salamandra, Sanofi, SC Pharma, Secretome, Sequana Medical, SQ Innovation, Tenex Health, Tricog Health, Ultromics, Vifor Pharma, and Zoll Medical. Dr Linde has received research support from the Swedish Heart Lung Foundation, the Swedish Society of Medical Sciences, the Stockholm County Council; consulting fees from AstraZeneca and Roche Diagnostics; and speaker honoraria from Novartis, AstraZeneca, Bayer, Vifor Pharma, Medtronic, and Impulse Dynamics; and has served on the advisory board of AstraZeneca. Dr Metra has received consulting honoraria for participation in steering committees, advisory boards, or speeches from Abbott Vascular, Amgen, AstraZeneca, Bayer, Edwards Lifesciences, Fresenius Medical Care, Novartis, and Servier (all outside of the submitted work). Dr Zieroth has received research grant support from, has served on the advisory boards of, or has speaker engagements with Abbott, AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, CSL Vifor, Cytokinetics, Edwards Lifesciences, Eli Lilly, GlaxoSmithKline, Medtronic, Merck, Novartis, Novo Nordisk, and Pfizer; and has served on the clinical trial committees for studies sponsored by AstraZeneca, Boehringer Ingelheim, Cytokinetics, Merck, Novartis, Pfizer, and Salubris Biotherapeutics. Dr Lund has received grants, consulting fees, and honoraria from Myocardia, AstraZeneca, Boehringer Ingelheim/Eli Lilly, Novartis, ACKNOWLEDGMENT The authors thank all staff members at care units in Sweden who report to the Swedish ICD and Pacemaker Registry for their contributions-
dc.language.isoen-
dc.publisherELSEVIER SCI LTD-
dc.rights2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. Thias is an Open Access article under the CC BY License (http://creativecommons.org/licenses/by/4.0/).-
dc.subject.othercardiac resynchronization therapy-
dc.subject.otherheart failure-
dc.subject.othermedical therapy-
dc.subject.othermorbidity-
dc.subject.othermortality-
dc.subject.otherregistry-
dc.subject.otherreal world-
dc.titleTiming of Cardiac Resynchronization Therapy Following Stable Medical Therapy in Patients With Heart Failure-
dc.typeJournal Contribution-
dc.identifier.issue10-
dc.identifier.volume13-
local.format.pages13-
local.bibliographicCitation.jcatA1-
dc.description.notesSavarese, G (corresponding author), Karolinska Inst, Dept Clin Sci & Educ, Sodersjukhuset, Sjukhusbacken 10, S-11883 Stockholm, Sweden.; Savarese, G (corresponding author), Karolinska Inst, Dept Clin Sci & Educ, Sodersjukhuset, Sjukhusbacken 10, S-11883 Stockholm, Sweden.-
dc.description.notesgianluigi.savarese@ki.se-
local.publisher.place125 London Wall, London, ENGLAND-
local.type.refereedRefereed-
local.type.specifiedArticle-
local.bibliographicCitation.artnr102515-
dc.identifier.doi10.1016/j.jchf.2025.102515-
dc.identifier.pmid40542793-
dc.identifier.isi001566680500001-
dc.contributor.orcidSavarese, Gianluigi/0000-0001-7732-0887; LInde,-
dc.contributor.orcidCecilia/0000-0002-9039-6023; Bozkurt, Biykem/0000-0002-6362-0253;-
local.provider.typewosris-
local.description.affiliation[Villaschi, Alessandro; Basile, Christian; Benson, Lina; Scorza, Raffaele; Savarese, Gianluigi] Karolinska Inst, Dept Clin Sci & Educ, Sodersjukhuset, Sjukhusbacken 10, S-11883 Stockholm, Sweden.-
local.description.affiliation[Villaschi, Alessandro; Condorelli, Gianluigi] Humanitas Univ, Dept Biomed Sci, Milan, Italy.-
local.description.affiliation[Basile, Christian] Univ Naples Federico II, Dept Adv Biomed Sci, Naples, Italy.-
local.description.affiliation[Benson, Lina; Gatti, Paolo; Linde, Cecilia; Lund, Lars H.; Gadler, Fredrik] Karolinska Inst, Dept Med, Div Cardiol, Stockholm, Sweden.-
local.description.affiliation[Gatti, Paolo] Sodertalje Hosp, Internal Med Unit, Sodertalje, Sweden.-
local.description.affiliation[Abraham, William T.] Ohio State Univ, Div Cardiovasc Med, Columbus, OH USA.-
local.description.affiliation[Bohm, Michael] Saarland Univ, Dept Internal Med 3, Homburg, Germany.-
local.description.affiliation[Bozkurt, Biykem] Baylor Coll Med, Dept Cardiol, Houston, TX USA.-
local.description.affiliation[Butler, Javed] Baylor Scott & White Res Inst, Dallas, TX USA.-
local.description.affiliation[Butler, Javed] Univ Mississippi, Dept Med, Jackson, MS USA.-
local.description.affiliation[Condorelli, Gianluigi] IRCCS Humanitas Res Hosp, Milan, Italy.-
local.description.affiliation[Metra, Marco] Univ Brescia, Dept Med & Surg Specialties, ASST Spedali Civili Brescia, Radiol Sci & Publ Hlth, Brescia, Italy.-
local.description.affiliation[Mullens, Wilfried] Ziekenhuis Oost Limburg, Dept Cardiol, Genk, Belgium.-
local.description.affiliation[Mullens, Wilfried] UHasselt Hasselt Univ, Biomed Res Inst, Fac Med & Life Sci, LCRC, Diepenbeek, Belgium.-
local.description.affiliation[Mol, Peter] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands.-
local.description.affiliation[Zieroth, Shelley] Univ Manitoba, Max Rady Coll Med, Sect Cardiol, Winnipeg, MB, Canada.-
local.uhasselt.internationalyes-
item.contributorVillaschi, Alessandro-
item.contributorBasile, Christian-
item.contributorBenson, Lina-
item.contributorGatti, Paolo-
item.contributorAbraham, William T.-
item.contributorBohm, Michael-
item.contributorBozkurt, Biykem-
item.contributorButler, Javed-
item.contributorCondorelli, Gianluigi-
item.contributorLinde, Cecilia-
item.contributorMetra, Marco-
item.contributorMULLENS, Wilfried-
item.contributorMol, Peter-
item.contributorZieroth, Shelley-
item.contributorScorza, Raffaele-
item.contributorLund, Lars H.-
item.contributorGadler, Fredrik-
item.contributorSavarese, Gianluigi-
item.fullcitationVillaschi, Alessandro; Basile, Christian; Benson, Lina; Gatti, Paolo; Abraham, William T.; Bohm, Michael; Bozkurt, Biykem; Butler, Javed; Condorelli, Gianluigi; Linde, Cecilia; Metra, Marco; MULLENS, Wilfried; Mol, Peter; Zieroth, Shelley; Scorza, Raffaele; Lund, Lars H.; Gadler, Fredrik & Savarese, Gianluigi (2025) Timing of Cardiac Resynchronization Therapy Following Stable Medical Therapy in Patients With Heart Failure. In: Jacc-heart Failure, 13 (10) (Art N° 102515).-
item.fulltextWith Fulltext-
item.accessRightsOpen Access-
crisitem.journal.issn2213-1779-
crisitem.journal.eissn2213-1787-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
Timing of Cardiac Resynchronization Therapy Following Stable Medical Therapy in Patients With Heart Failure.pdfPublished version3.26 MBAdobe PDFView/Open
Show simple item record

SCOPUSTM   
Citations

3
checked on Oct 4, 2025

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.